Volatility and Risk
Revelation Biosciences has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, Emmaus Life Sciences has a beta of 6.22, indicating that its stock price is 522% more volatile than the S&P 500.
Institutional & Insider Ownership
12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 7.4% of Emmaus Life Sciences shares are owned by institutional investors. 0.2% of Revelation Biosciences shares are owned by company insiders. Comparatively, 35.0% of Emmaus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Revelation Biosciences and Emmaus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revelation Biosciences | N/A | -193.51% | -84.00% |
| Emmaus Life Sciences | -17.11% | N/A | -12.66% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revelation Biosciences | N/A | N/A | -$120,000.00 | ($16.76) | -0.03 |
| Emmaus Life Sciences | $29.60 million | 0.04 | -$3.73 million | ($0.09) | -0.19 |
Revelation Biosciences has higher earnings, but lower revenue than Emmaus Life Sciences. Emmaus Life Sciences is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Emmaus Life Sciences beats Revelation Biosciences on 6 of the 10 factors compared between the two stocks.
About Revelation Biosciences
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
